NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Actuate Therapeutics Inc.
OHSU Knight Cancer Institute
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Imunon
University of Iowa
Washington University School of Medicine